- Home
- HUHU vs ARMP Comparison
HUHU vs ARMP Comparison
Compare HUHU & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUHU
- ARMP
- Stock Information
- Founded
- HUHU 2015
- ARMP N/A
- Country
- HUHU China
- ARMP United States
- Employees
- HUHU N/A
- ARMP N/A
- Industry
- HUHU
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HUHU
- ARMP Health Care
- Exchange
- HUHU NYSE
- ARMP Nasdaq
- Market Cap
- HUHU N/A
- ARMP 80.0M
- IPO Year
- HUHU 2024
- ARMP N/A
- Fundamental
- Price
- HUHU $4.70
- ARMP $1.95
- Analyst Decision
- HUHU
- ARMP Strong Buy
- Analyst Count
- HUHU 0
- ARMP 1
- Target Price
- HUHU N/A
- ARMP $7.00
- AVG Volume (30 Days)
- HUHU 152.2K
- ARMP 13.2K
- Earning Date
- HUHU 02-22-2025
- ARMP 11-13-2024
- Dividend Yield
- HUHU N/A
- ARMP N/A
- EPS Growth
- HUHU 13.14
- ARMP N/A
- EPS
- HUHU 0.08
- ARMP N/A
- Revenue
- HUHU $17,492,735.00
- ARMP $5,467,000.00
- Revenue This Year
- HUHU N/A
- ARMP N/A
- Revenue Next Year
- HUHU N/A
- ARMP $83.33
- P/E Ratio
- HUHU $57.60
- ARMP N/A
- Revenue Growth
- HUHU 33.03
- ARMP 34.92
- 52 Week Low
- HUHU $3.52
- ARMP $1.80
- 52 Week High
- HUHU $9.89
- ARMP $4.48
- Technical
- Relative Strength Index (RSI)
- HUHU N/A
- ARMP 42.89
- Support Level
- HUHU N/A
- ARMP $1.80
- Resistance Level
- HUHU N/A
- ARMP $2.22
- Average True Range (ATR)
- HUHU 0.00
- ARMP 0.13
- MACD
- HUHU 0.00
- ARMP -0.01
- Stochastic Oscillator
- HUHU 0.00
- ARMP 35.48
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.